Skip to content

Parkinson's Disease Dementia

Parkinson’s disease dementia occurs when the cognitive changes that can accompany Parkinson’s become significant enough to interfere with daily life. It typically emerges years after motor symptoms begin, and is distinct from Alzheimer’s disease, though the two can overlap. In ageing populations, Parkinson’s disease is increasingly recognised, making awareness of its later-stage complications more important.

Exelon

Rivastigmine

1.5 · 3mg

Rivastigmine 1.5mg and 3mg hard capsules, used in the management of Alzheimer's dementia and Parkinson's disease dementia. A cholinesterase inhibitor.

From$0.77/ tabletView

Key points

  • Thinking difficulties linked to Parkinson’s can eventually disrupt daily life, typically appearing years after the first movement symptoms.
  • The pattern centres on attention, mental speed and judging distances rather than the memory loss typical of Alzheimer’s.
  • Seeing things that are not there, along with low mood or anxiety, often accompany the cognitive changes.
  • Among available drugs, rivastigmine has the best supporting evidence and sees the widest use for this particular form of dementia.

How cognition is affected

The cognitive profile in Parkinson’s disease dementia tends to centre on attention, processing speed, and visual-spatial skills rather than the memory-first pattern seen in Alzheimer’s. People may struggle to concentrate, lose track of conversations, or have difficulty judging distances. Hallucinations and mood disturbances, including depression and anxiety, are also common.

Approaches to managing symptoms

There is no cure, but cognitive symptoms can be moderated. Within neurology, the cholinesterase inhibitor rivastigmine has the strongest evidence base for Parkinson’s disease dementia and is the treatment most widely used. Non-drug strategies, such as structured daily routines, cognitive stimulation, and carer support, complement medical management and help maintain quality of life.

Further reading